Posted by Michael Wonder on 02 Aug 2021
Uptravi (selexipag) receives FDA approval for intravenous use in adult patients with pulmonary arterial hypertension
30 July 2021 - New formulation allows for uninterrupted treatment for pulmonary arterial hypertension patients temporarily unable to take oral therapy.
Janssen announced today that the U.S. FDA has approved Uptravi (selexipag) injection for intravenous use for the treatment of pulmonary arterial hypertension (WHO Group I) in adult patients with WHO functional class II–III, who are temporarily unable to take oral therapy.
